Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...

HYDERABAD: Dr Reddy’s Labs on Wednesday said its subsidiary, Dr Reddy’s Labs SA, has entered into commercialisation and ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment.

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Bio-Thera and Dr. Reddy's partner for biosimilar commercialization in Southeast Asia, expanding access to affordable ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Hyderabad: Dr Reddy's Labs (DRL) on Wednesday said its subsidiary, Dr Reddy's Labs SA, entered into commercialisation and ...